2. Disease Areas
  3. Cancer Digestive System Disease
  4. Pancreatic Cancer Digestive System Cancer
  5. Pancreatic Ductal Adenocarcinoma

Pancreatic Ductal Adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is the most common and aggressive form of pancreatic cancer, arising from the ductal cells of the pancreas that produce digestive enzymes. It is an exocrine tumor characterized by solid, firm, and poorly defined masses typically diagnosed at 2.5–3 cm in size. PDAC is highly lethal due to its late diagnosis, limited treatment response, and rapid progression. Common symptoms include abdominal pain, weight loss, loss of appetite, and jaundice, often appearing only in advanced stages. Diagnosis relies on imaging techniques such as CT or MRI, followed by biopsy confirmation. While surgical resection offers the only potential cure, it is feasible in only about 20% of cases. Chemotherapy and radiation therapy are used to manage symptoms and improve quality of life. The prognosis remains extremely poor, with a 5-year survival rate of 5% to 15% and an overall survival rate of just 6%, making PDAC one of the deadliest cancers.

Pancreatic Ductal Adenocarcinoma (18):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-145928
    Divarasib 2417987-45-0 99.31%
    Divarasib (GDC-6036) is an orally active, selective KRASG12C inhibitor with an IC50 of <0.01 μM. Divarasib covalently binds Cys12 in GDP-bound KRASG12C, occupies the switch II pocket, blocks GTP binding and SOS-mediated reactivation, and inhibits oncogenic KRAS signaling. Divarasib induces tumor shrinkage and robust tumor growth inhibition in KRASG12C-positive models and cancer cells. Divarasib can be used for the research of non-small cell lung cancer, colorectal adenocarcinoma, pancreatic ductal adenocarcinoma, and other KRASG12C-mutated solid tumors.
    Divarasib
  • HY-173629
    RMC-5127 3082166-76-2 99.96%
    RMC-5127 is a small molecule inhibitor that binds to GTP-targeted KRASG12V, with oral bioavailability and blood-brain barrier permeability. RMC-5127 inhibits the activities of the RAS and MAPK pathways, suppresses the proliferation of KRASG12V-mutant cancer cells and induces their apoptosis. RMC-5127 can be used for the research of KRASG12V-mutant non-small cell lung cancer, pancreatic ductal adenocarcinoma, colorectal cancer and intracranial KRASG12V tumors.
    RMC-5127
  • HY-W087027
    Maleimide-NOTA 1295584-83-6 99.69%
    Maleimide-NOTA is a chelate. Maleimide-NOTA can be site-specifically coupled to the hPD-L1 nanobody bearing the Cys-tag. Maleimide-NOTA can specifically conjugate to A20FMDV2 (HY-P1654). The [68Ga]Ac-CG6 formed by the conjugation of 68Ga radiolabeled Maleimide-NOTA with A20FMDV2 can be used for PET imaging of αvβ6 integrin-positive pancreatic ductal adenocarcinoma.
    Maleimide-NOTA
  • HY-145928B
    Divarasib adipate 2762240-36-6 99.20%
    Divarasib (GDC-6036) adipate is an orally active, selective KRASG12C inhibitor with an IC50 of <0.01 μM. Divarasib adipate covalently binds Cys12 in GDP-bound KRASG12C, occupies the switch II pocket, blocks GTP binding and SOS-mediated reactivation, and inhibits oncogenic KRAS signaling. Divarasib adipate induces tumor shrinkage and robust tumor growth inhibition in KRASG12C-positive models and cancer cells. Divarasib adipate can be used for the research of non-small cell lung cancer, colorectal adenocarcinoma, pancreatic ductal adenocarcinoma, and other KRASG12C-mutated solid tumors.
    Divarasib adipate
  • HY-162567
    AP-4-139B 2716909-84-9 98.87%
    AP-4-139B is a blood-brain barrier-permeable HSP70 inhibitor with a IC50 of 180 nM against hHSP70. AP-4-139B binds directly to HSP70 and inhibits its ATPase activity. AP-4-139B promotes Autophagy by increasing the phosphorylation of Beclin-1. AP-4-139B exerts antitumor effects in preclinical models of colorectal cancer and pancreatic ductal adenocarcinoma.
    AP-4-139B
  • HY-183786
    Anticancer agent 327
    Anticancer agent 327, a fluorescent Andrographolide (HY-N0191) derivative, is an NF-κB p50 inhibitor. Anticancer agent 327 covalently binds to the p50 subunit of NF-κB. Anticancer agent 327 reduces levels of multiple oncogenic p53 proteins via the autophagy/lysosome pathway. Anticancer agent 327 can be used for the research of pancreatic ductal adenocarcinoma (Ex/Em = 488/515 nm)[1].
    Anticancer agent 327
  • HY-P992350
    EBC-129 Antibody
    EBC-129 Antibody is a specific antibody for the synthetic antibody-drug conjugate (ADC) EBC-129, which specifically targets CEACAM5 and CEACAM6 glycosylated at N256. EBC-129 Antibody can be used for the research of pancreatic ductal adenocarcinoma.
    EBC-129 Antibody
  • HY-177244
    EBET-1593 3031540-97-0
    EBET-1593 is a BET PROTAC degrader. EBET-1593 can promote the ubiquitination and degradation of BET. EBET-1593 is a lead payload. EBET-1593 can be used to synthesize ADCs, such as 84-EBET. 84-EBET has antitumor effects against pancreatic ductal adenocarcinoma.
    EBET-1593
  • HY-161767
    JWJ-01-306 3069975-17-0
    JWJ-01-306 is a CRBN-recruiting ZBTB11 Molecular Glues degrader. JWJ-01-306 degrades ZBTB11 and reprograms cellular metabolism, thereby reducing the level of Oxidative Phosphorylation and the activity of the tricarboxylic acid cycle. JWJ-01-306 enhances the response of organoids to K-Ras inhibition. JWJ-01-306 inhibits the proliferation of pancreatic ductal adenocarcinoma cells and melanoma cells. JWJ-01-306 can be used in studies related to pancreatic ductal adenocarcinoma and melanoma.
    JWJ-01-306
  • HY-186196
    Fentomycin-1 3095435-04-1
    Fentomycin-1 is a ferroptosis inducer. Fentomycin-1 activates lysosomal iron2+ under acidic conditions with hydrogen peroxide to form a reactive iron-oxo species, which induces oxidative degradation, oxidation, and lipolysis of membrane phospholipids, triggering ferroptosis. Fentomycin-1 can be used for the research of pancreatic ductal adenocarcinoma, breast cancer metastasis, and melanoma.
    Fentomycin-1
  • HY-P992464
    SHR-A1403 Antibody
    SHR-A1403 Antibody is an anti-c-Met monoclonal antibody. SHR-A1403 Antibody down-regulates phosphorylated c-Met, Akt, ERK, weakens intracellular signal cascades, and mediates antibody-c-Met complex endocytosis. SHR-A1403 Antibody can be used for the research of c-met-overexpressing cancers and pancreatic ductal adenocarcinoma.
    SHR-A1403 Antibody
  • HY-P992379
    IB001
    IB001 is a humanized anti-BAG3 antibody that inhibits BAG3, with a KD value of 14.4 nM for human BAG3. IB001 blocks BAG3-dependent monocyte/macrophage activation, interferes with the interaction between BAG3 and IFITM-2, and disrupts tumor microenvironment signaling pathways. IB001 inhibits tumor growth, reduces α-SMA-positive fibroblasts, and blocks BAG3-dependent IL-6 release. IB001 accumulates in a time-dependent manner in pancreatic ductal adenocarcinoma tumors. IB001 can be used for research related to pancreatic ductal adenocarcinoma.
    IB001
  • HY-183098
    UNC8209
    UNC8209 is a selective PROTAC-based TANK-binding kinase 1 (TBK1) degrader. UNC8209 recruits cereblon (CRBN) to mediate ubiquitin-proteasome pathway-dependent TBK1 degradation and reduces AAK1, GAK, and AURKA abundance. UNC8209 suppresses tumor cell proliferation, impairs in vivo tumor growth, inhibits colony and clonogenic growth and enhances tumor cell sensitivity to TNFα or IFN-γ. UNC8209 modulates cell cycle and induces mild apoptosis. UNC8209 can be used for the research of clear cell renal cell carcinoma, non-small cell lung cancer, pancreatic ductal adenocarcinoma.
    UNC8209
  • HY-182241
    JR4-187 2446965-01-9
    JR4-187 is an orally active, copper-dependent anticancer agent. JR4-187 downregulates genes involved in oxidative phosphorylation, MYC targets and E2F targets in cancer cells, while upregulates genes involved in the TNF-α signaling pathway, p53 pathway and KRAS signaling pathway, and downregulates CTR1 protein. JR4-187 induces ROS production, apoptosis, copper-dependent cytotoxicity, and exhibits selective cytotoxicity against KRAS-mutant cancer cells. JR4-187 is well tolerated in mouse models of pancreatic cancer. JR4-187 can be used in research related to cancers such as pancreatic ductal adenocarcinoma, colon cancer and rectal cancer.
    JR4-187
  • HY-134505
    Avicin G 197787-17-0
    Avicin G is a sphingomyelinase inhibitor and plasma membrane disruptor. Avicin G inhibits the enzymatic activities of neutral sphingomyelinases (SMPD2/3) and acid sphingomyelinase (SMPD1), elevates intracellular sphingomyelin levels, and alters the distribution of sphingomyelin. Avicin G interferes with the lateral segregation of GTP- and GDP-bound H-Ras, inhibits the signal output of oncogenic K-Ras and H-Ras, reduces the phosphorylation of ERK and Akt, increases lysosomal pH, and inhibits the endocytic recycling of epidermal growth factor receptor. Avicin G can be used in research related to pancreatic ductal adenocarcinoma and non-small cell lung cancer.
    Avicin G
  • HY-180920
    KRAS G12D-IN-36
    KRAS G12D-IN-36 (Compound 53a) is a highly selective and orally active KRAS-G12D inhibitor with an IC50 of 1.63 nM. KRAS G12D-IN-36 effectively inhibits p-ERK with an IC50 of 8.4 nM. KRAS G12D-IN-36 shows potent anti-proliferative activity against AsPC-1 cells. KRAS G12D-IN-36 can be used for research on pancreatic cancer.
    KRAS G12D-IN-36
  • HY-P991973
    HuL001
    HuL001 is a specific monoclonal antibody targeting ENO1. HuL001 remodels the tumor microenvironment by inhibiting cancer-associated fibroblasts, thereby suppressing the progression of multiple myeloma. HuL001 can be used for research on cancers such as colorectal cancer, pancreatic ductal adenocarcinoma, and myeloma.
    HuL001
  • HY-N14093
    Aspulvinone H 57744-69-1
    Aspulvinone H is an orally active inhibitor of AChE, pancreatic lipase, glutamic-oxaloacetic transaminase 1, and α-glucosidase, with IC50 values of 25.95 μM, 47.06 μM, 5.91/6.91 μM, and 4.6 μM, respectively. It has a Ka of 2.14 μM against GOT1 and a Ki of 6.58 μM against α-glucosidase. Aspulvinone H inhibits cancer cell proliferation, interferes with glutamine metabolism, elevates ROS levels, and induces cell apoptosis and S-phase arrest. Aspulvinone H exhibits antibacterial activity against Staphylococcus aureus. Aspulvinone H inhibits the growth of pancreatic ductal adenocarcinoma xenografts. Aspulvinone H reduces postprandial blood glucose in mice. Aspulvinone H can be used in research related to pancreatic ductal adenocarcinoma, diabetes, and Staphylococcus aureus infection.
    Aspulvinone H